Tag: sartor

Quick Search


Bone -Targeted Therapy for Advanced Prostate Cancer

Sun 31 May 2009

Oliver Sartor, MD Tulane University, New Orleans, LA Edited from PCRI Insights May, 2009 v 12.2 Editor’s Note: Dr. Sartor provided this updated version of a paper he presented at the ASCO Genitourinary Cancers Symposium 2009 From several perspectives, bone disease is of particular interest for those treating patients with advanced prostate cancer. First, androgenRead More ›

Chicago Town Hall 2006

Sat 17 Jun 2006

Chicago “Town Hall Meeting” Creates Spirited Discussion On Saturday June 17, 2006, six prostate cancer specialists participated in a “spirited” discussion regarding treatment options for patients with hormone refractory and advanced prostate cancer. The meeting was produced by PCRI and underwritten by an educational grant from Abbott Oncology. It was held at the Hyatt RegencyRead More ›

Hormone-Refractory Prostate Cancer: A Continuum of Diseases and Options

Tue 1 Nov 2005

By Oliver Sartor, M.D., Chief, Hematology-Oncology Section; Director, Stanley S. Scott Cancer Center, LSU Medical Center, New Orleans Edited from PCRI Insights November, 2005 vol. 8 no.4 Introduction It is possible that hormones can sometimes cure, but unfortunately, that seems to be true only in a minority of patients. Certainly if the disease has becomeRead More ›

Newer Concepts in the Treatment of Hormone-Refractory Prostate Cancer with Bone Metastases: Combinations of Bone-Seeking Radiopharmaceuticals and Chemotherapy

Sun 1 May 2005

PCRI Insights May 2005 vol. 8, no. 2 By Oliver Sartor, MD Chief, Hematology-Oncology Section; Director, Stanley S. Scott Cancer Center, LSU Health Sciences Center, New Orleans, LA PAIN FROM BONE METASTASIS IS ONE OF THE MOST DIFFICULT CLINICAL PROBLEMS IN PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER (HRPC). Radiographic evidence of distant metastatic spread to boneRead More ›